創勝集團－Ｂ
B6-501, 218 Xinghu Street
Biobay
Suzhou 215123
China
86 21 6237 0929
https://www.transcenta.com
版塊: Healthcare
行業: Biotechnology
全職員工: 215
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Xueming Qian Ph.D. | CEO & Executive Director | 3.58M | 無 | 1969 |
| Mr. Xiaolu Weng CPA | Executive VP & CFO | 3.81M | 無 | 1977 |
| Dr. Feng Ye Ph.D. | Executive VP & COO | 無 | 無 | 1969 |
| Dr. Christopher Hwang Ph.D. | Executive VP & CTO | 無 | 無 | 1965 |
| Ms. Wei Wang | VP of Investor Relations & Capital Markets Department and Secretary to the Board | 無 | 無 | 1983 |
| Dr. Yi Gu Ph.D. | Senior VP & Head of Research | 無 | 無 | 1969 |
| Dr. Charlie Qi M.D. | Senior Vice President of Global Clinical Development | 無 | 無 | 無 |
| Dr. Xichen Zhang Ph.D. | Senior Vice President of Manufacturing | 無 | 無 | 無 |
| Dr. Wen-I Chang Ph.D. | Senior Vice President of Oncology Franchise Strategy | 無 | 無 | 無 |
| Dr. Caroline Germa M.D., Ph.D. | Executive VP of Global Medicine Development & Chief Medical Officer | 無 | 無 | 1972 |
描述
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST005, a PD-L1/TGF-ß bi-functional protein candidate for solid tumors; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing; TST003, a regulatory protein expressed by stromal cells and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST006, a bi-specific claudin 18.2/PD-L1 antibody for solid tumors; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors; MSB2311, A humanized PD-L1 mAb candidate for solid tumors; TST012 and TST013, an ADC candidate targeting biomarker expressing gastric cancer and other solid tumors; and TST801, a bifunctional fusion protein for autoimmune diseases. The company has a partnership and collaboration agreements with Bristol Myers Squibb and Eli Lilly & Company; research collaboration with Alebund Pharmaceuticals, Dana Farber Cancer Institute, and John Hopkins University; and technology collaboration with Merck KGaA. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.
公司管治
截至 無 止，創勝集團－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
